{
    "nct_id": "NCT03338790",
    "official_title": "A Phase 2 Study of Nivolumab in Combination With Either Rucaparib, Docetaxel, or Enzalutamide in Men With Castration-resistant Metastatic Prostate Cancer",
    "inclusion_criteria": "* Histologic confirmation of adenocarcinoma of the prostate\n* Evidence of stage IV disease on previous bone, CT, and/or MRI scan\n* Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy\n* Mandatory plasma and fresh or archival tumor tissue must be submitted\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the breast\n* Participants with active brain metastases\n* Participants must have recovered from the effects of major surgery requiring general anesthesia or significant traumatic injury at least 14 days before treatment arm assignment\n\nOther protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": ""
}